

GRO- α /CXCL1 Protein, Human

Cat. No.:	HY-P7187
Synonyms:	rHuGRO- α /CXCL1; NAP-3; MGSA; Growth-regulated alpha protein
Species:	Human
Source:	E. coli
Accession:	P09341 (A35-N107)
Gene ID:	2919
Molecular Weight:	Approximately 7.8 kDa

PROPERTIES

AA Sequence	A S V A T E L R C Q C L Q T L Q G I H P K N I Q S V N V K S P G P H C A Q T E V I A T L K N G R K A C L N P A S P I V K K I I E K M L N S D K S N
Biological Activity	The ED ₅₀ is <100 ng/mL as measured by CHO-K1/G α 15/hCXCR2 cells (human G α 15 and human CXCR2 stably expressed in CHO-K1 cells).
Appearance	Lyophilized powder.
Formulation	Lyophilized after extensive dialysis against PBS.
Endotoxin Level	<0.2 EU/ μ g, determined by LAL method.
Reconstitution	It is not recommended to reconstitute to a concentration less than 100 μ g/mL in ddH ₂ O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background	<p>CXCL1, also known as GRO-α, is a polypeptide that is initially isolated from human melanoma cells. CXCL1 acts as a key chemoattractant for neutrophils by binding specifically to its corresponding G-protein-coupled receptor CXCR2. CXCL1 modulates angiogenesis, tumorigenesis, and wound healing. In general, CXCL1 levels are extremely low under normal physiological conditions and greatly increased during inflammatory conditions^{[2][3]}.</p> <p>The amino acid sequence of human CXCL1 protein has low homology between mouse and rat CXCL1 protein. After translation, the synthesized CXCL1 precursor is 107aa long. A signal peptide is removed from its N-terminus, which shortens the precursor to 73aa. Two other amino acids can also be removed from the C-terminus. In addition, two disulfide</p>
-------------------	---

bridges are formed from all four cysteine residues in CXCL1. The disulfide bridges give the appropriate structure to CXCL1, which determines the properties of this chemokine. After secretion, CXCL1 undergoes further proteolytic processing, which regulates the activity of this chemokine. From the N-terminus, three, four or five amino acids are removed, which produce CXCL1(4-73), CXCL1(5-73), and CXCL1(6-73), respectively. This increases CXCL1 activity 30 times, as measured by its ability to induce the chemotaxis of treated cells. To date, three CXCL1 receptors have been discovered-CXCR1, CXCR2 and atypical chemokine receptor 1 (ACKR1). Through NF- κ B activation, CXCL1 expression is increased by cytokines such as IL-1 β , TNF- α and IL-17. CXCL1 can associate into bioactive dimers and primarily signals through CXCR2/IL-8 RB^[1].

After CXCL1 expression is induced by carcinogens, it participates in inflammatory responses by recruiting neutrophils. This leads to chronic inflammation. In addition to increasing proliferation, CXCL1 also induces cancer cell migration, particularly EMT. Produced by lymphatic endothelial cells (LECs), CXCL1 enables tumor cell migration into the lymphatic vessels during lymphangiogenesis, leading to lymph node metastasis. CXCL1 is a chemotactic factor for neutrophils. Additionally, it causes the mobilization of these cells from the bone marrow. CXCL1 can also induce recruitment of regulatory T cells (Treg) and MSCs into the tumor niche. Another no-less-important property of CXCL1 is its ability to induce angiogenesis^[1].

REFERENCES

- [1]. Dhawan P, et al. Role of CXCL1 in tumorigenesis of melanoma. *J Leukoc Biol.* 2002 Jul;72(1):9-18.
- [2]. Haskill S, et al. Identification of three related human GRO genes encoding cytokine functions. *Proc Natl Acad Sci U S A.* 1990 Oct;87(19):7732-6.
- [3]. Moser B, et al. Neutrophil-activating properties of the melanoma growth-stimulatory activity. *J Exp Med.* 1990 May 1;171(5):1797-802.
- [4]. Vries MH, et al. CXCL1 promotes arteriogenesis through enhanced monocyte recruitment into the peri-collateral space. *Angiogenesis.* 2015 Apr;18(2):163-71.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA